Breaking News

Trials & Filings in Brief: Jan. 7, 2014

By Gil Roth | January 7, 2014

Alitair, Celgene, Erytech, Galena, Neurocrine, Orexigen, Shield, TeaRx

Phase II
Erytech to begin pancreatic cancer study . . . read more

Galena enrolls first ovarian cancer patient . . . read more

Neurocrine Biosciences posts positive results in tardive dyskinesia . . . read more

TeaRx begins anticoagulant trial . . . read more

Phase III
Positive results for Shield's IDA treatment in IBD . . . read more

Celgene's Abraxane approved in EU for pancreatic cancer . . . read more

Alitair gets orphan status for bronchiectasis treatment . . . read more

Orexigen gets Contrave PDUFA date . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials